Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
BMC Neurosci ; 19(1): 58, 2018 Sep 21.
Artigo em Inglês | MEDLINE | ID: mdl-30241502

RESUMO

BACKGROUND: Minocycline is a lipophilic tetracycline of increasing appeal in neuroscience as it inhibits microglial activation, a mechanism involved in numerous neuropsychiatric disorders. Own data point towards retinoid-mediated effects of minocycline in murine brain and skin, and towards a vicious cycle of neuroinflammation which is driven by microglial activation-induced breakdown of local retinoids such as retinoic acid (RA). We therefore sought to study minocycline's anti-inflammatory effects on human microglial-like monocyte-derived cells in the context of retinoid signaling. RESULTS: As hypothesized, minocycline exposure resulted in a substantial increase of RA levels in the human monocytic cell line THP-1. While pro-inflammatory stimulation with lipopolysaccharides resulted in increased tryptophane-degrading indoleamine-2,3-dioxygenase IDO-expression and TNF-α levels in primary human monocyte-derived microglial-like cells, this effect was attenuated by minocycline only in the presence of retinoids. The anti-inflammatory effects of minocycline on TNF-α expression were completely abolished by a pharmacological blockage of retinoic acid receptors (RARs) using BMS-493 and unaffected by selectively blocking retinoid-X-receptors using UVI-3003. CONCLUSIONS: Our data indicate for the first time a RA-dependent, anti-inflammatory effect for minocycline in human microglial-like cells via inhibition of local RA turnover. The RA-dependent mode of action for minocycline appears to be predominantly mediated through RAR-signaling.


Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Minociclina/farmacologia , Receptores do Ácido Retinoico/metabolismo , Tretinoína/metabolismo , Benzoatos/farmacologia , Ácidos Cumáricos/farmacologia , Humanos , Indolamina-Pirrol 2,3,-Dioxigenase/metabolismo , Interleucina-6/metabolismo , Quinurenina 3-Mono-Oxigenase/metabolismo , Lipopolissacarídeos , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Microglia/efeitos dos fármacos , Microglia/metabolismo , Monócitos/efeitos dos fármacos , Monócitos/metabolismo , Receptores do Ácido Retinoico/antagonistas & inibidores , Estilbenos/farmacologia , Células THP-1 , Tetra-Hidronaftalenos/farmacologia , Fator de Necrose Tumoral alfa/metabolismo
2.
Toxicol Appl Pharmacol ; 316: 10-16, 2017 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-27939987

RESUMO

Use of the atypical antipsychotic clozapine (CZP) is compromised by the risk of potentially fatal agranulocytosis/granulocytopenia (CIAG). To address this, we have established a simple, personalized cell culture-based strategy to identify CIAG-susceptible patients, hypothesizing that an immunogenic and possibly haptene-based mechanism underlies CIAG pathophysiology. To detect a putative haptene-induced response to CZP in vitro exposure, a traditional lymphocyte stimulation assay was adapted and applied to patient-specific peripheral blood-derived mononuclear cells (PBMC). 6 patients with a history of CIAG, 6 patients under CZP treatment (without CIAG) and 12 matched healthy controls were studied. In vitro CZP exposure, even at strikingly low levels, resulted in significantly increased proliferation rates only in CIAG patients' PBMC. Other parameters including cell viability and mitogen-induced proliferation were also affected by in vitro CZP exposure, yet there was no significant difference between the groups. This personalized approach is a starting point for further investigations into a putative haptene-based mechanism underlying CIAG development, and may facilitate the future development of predictive testing.


Assuntos
Agranulocitose/induzido quimicamente , Agranulocitose/imunologia , Antipsicóticos/efeitos adversos , Clozapina/efeitos adversos , Imunidade Celular/efeitos dos fármacos , Imunidade Celular/imunologia , Antipsicóticos/uso terapêutico , Proliferação de Células/efeitos dos fármacos , Proliferação de Células/fisiologia , Sobrevivência Celular/efeitos dos fármacos , Sobrevivência Celular/imunologia , Células Cultivadas , Clozapina/uso terapêutico , Relação Dose-Resposta a Droga , Humanos , Leucócitos Mononucleares/efeitos dos fármacos , Leucócitos Mononucleares/imunologia , Esquizofrenia/tratamento farmacológico , Esquizofrenia/imunologia
3.
Exp Dermatol ; 24(6): 473-6, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25810318

RESUMO

Retinoic acid (RA) represents an essential and highly potent endogenous retinoid with pronounced anti-inflammatory properties and potent anti-acne activity, and has recently been suggested to share a common anti-inflammatory mode of action with tetracycline antibiotics. We hypothesized that tetracyclines may directly interfere with RA homeostasis via inhibition of its local cytochrome P450 (CYP450)-mediated degradation, an essential component of tightly regulated skin RA homeostasis. To test this hypothesis, we performed controlled in vitro RA metabolism assays using rat skin microsomes and measured RA levels in a RA-synthesizing human keratinocyte cell line, both in the presence and in the absence of minocycline, a tetracycline popular in acne treatment. Interestingly, minocycline potently blocked RA degradation in rat skin microsomes, and strikingly enhanced RA levels in RA-synthesizing cell cultures, in a dose-dependent manner. These findings indicate a potential role for CYP-450-mediated RA metabolism in minocycline's pleiotropic mode of action and anti-acne efficacy and could account for the overlap between minocycline and RA-induced effects at the level of their molecular mode of action, but also clinically at the level of the rare side effect of pseudotumor cerebri, which is observed for both, RA and minocycline treatment.


Assuntos
Antibacterianos/farmacologia , Minociclina/farmacologia , Tretinoína/antagonistas & inibidores , Tretinoína/metabolismo , Animais , Linhagem Celular , Relação Dose-Resposta a Droga , Homeostase/efeitos dos fármacos , Humanos , Técnicas In Vitro , Queratinócitos/citologia , Queratinócitos/efeitos dos fármacos , Queratinócitos/metabolismo , Metabolismo/efeitos dos fármacos , Modelos Animais , Ratos , Pele/citologia , Pele/efeitos dos fármacos , Pele/metabolismo
4.
J Alzheimers Dis ; 61(4): 1295-1300, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29376871

RESUMO

Apolipoprotein E (ApoE) represents a pivotal target in Alzheimer's disease (AD) and is modulated through retinoic acid (RA), an endogenous neuroprotective and anti-inflammatory compound. A major source of ApoE are microglia, which are pathologically activated in AD. Activated microglia are known to block RA signaling. This suggests a vicious cycle between inflammation, RA signaling, and ApoE homeostasis in AD pathogenesis. To test this hypothesis, we investigated effects of RA and proinflammatory activation on ApoE synthesis in primary human macrophage-derived microglial-like cells. Our results indicate that proinflammatory activation attenuates ApoE synthesis, an effect blocked by RA.


Assuntos
Apolipoproteínas E/metabolismo , Macrófagos/efeitos dos fármacos , Tretinoína/farmacologia , Doença de Alzheimer/metabolismo , Apolipoproteínas E/genética , Células Cultivadas , Humanos , Macrófagos/metabolismo , Transdução de Sinais/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa